Detalles de la búsqueda
1.
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.
Cancer Res Treat;
56(1): 48-60, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37402411
2.
Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study.
Cancer Res Treat;
56(2): 404-413, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37933112
3.
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
Cancer;
130(4): 541-552, 2024 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37843249
4.
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
J Thorac Oncol;
18(10): 1351-1361, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37702629
5.
Risk factors of menopause after allogeneic hematopoietic cell transplantation in premenopausal adult women.
Eur J Haematol;
111(3): 449-457, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308461
6.
The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation.
BMC Cancer;
22(1): 997, 2022 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36127634
7.
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22.
Transl Lung Cancer Res;
11(7): 1369-1379, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35958320
8.
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
Korean J Intern Med;
37(4): 841-850, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35811370
9.
Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors.
Cancers (Basel);
14(14)2022 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35884501
10.
Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling.
PLoS One;
17(5): e0265958, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35503759
11.
The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study.
Cancer Med;
11(3): 705-714, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34889062
12.
Author Correction: Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.
Sci Rep;
11(1): 23281, 2021 Nov 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34837004
13.
The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway.
Sci Rep;
11(1): 13198, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34168229
14.
Unmet needs related to the quality of life of advanced cancer patients in Korea: a qualitative study.
BMC Palliat Care;
20(1): 58, 2021 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33849508
15.
Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act.
BMC Palliat Care;
20(1): 63, 2021 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33906659
16.
LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells.
PLoS One;
16(2): e0247368, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33606781
17.
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
J Cancer Res Clin Oncol;
147(8): 2459-2469, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33523301
18.
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
BMC Cancer;
20(1): 1193, 2020 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33276759
19.
Correction: The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors.
Clin Cancer Res;
26(24): 6610, 2020 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33323362
20.
Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma.
Cancer;
126(20): 4521-4531, 2020 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32749686